0
Abstract: Slide Presentations |

Early vs delayed initiation of fondaparinux prophylaxis to prevent postoperative pulmonary embolism: A clinical endpoint study FREE TO VIEW

Bruce Davidson, MD*; A.G.G. Turpie, MD; Clifford Colwell, MD; Louis M. Kwong, MD
Author and Funding Information

University of Washington and Swedish Medical Center, Seattle, WA


Chest


Chest. 2004;126(4_MeetingAbstracts):783S. doi:10.1378/chest.126.4_MeetingAbstracts.783S-b
Text Size: A A A
Published online

Abstract

PURPOSE:  Highly effectve thromboembolism prophylaxis is underused because of concern about excessive bleeding risk and doubt about the clinical relevance of studies which reported asymptomatic venographic outcomes. One popular review concludes prophylaxis must be given close to surgery for optimum effectiveness. To address these issues, we tested the highly effective sq antithrombotic fondaparinux, a factor Xa inhibitor, initiated either 6-8 h after surgery (“early”) vs the next morning (“delayed”) in joint replacement patients.

METHODS:  Drug administration and observations were unblinded but adjudication of thromboembolism (VTE), bleeding, and cause of death were blinded. Outcomes were clinically symptomatic and objectively documented thromboembolism, major and clinically relevant non-major bleeding, and death due to complications of bleeding or thrombosis during the 6 weeks after surgery.

RESULTS:  2000 patients, 1003 early and 997 delayed, were randomized and received at least one dose of assigned treatment. Among the early group, 19 had VTE (1.9%; 10 DVTs and 9 PEs). Among the delayed group, 18 had VTE (1.8%; 11 DVTs and 9 PEs, 2 patients with both). There were 4 deaths in the early group vs 1 in the delayed group (P=0.4), none related to VTE or bleeding. There were 12 major and 14 clinically relevant non-major bleeds in the early group, vs 7 and 19 respectively for the delayed group (P=0.4 for major bleeding). The early and late dosed groups appeared similar in other respects also.

CONCLUSION:  In 2000 surgical patients, clinically evident thromboembolism risk over 6 weeks was no higher if initiation of highly effective prophylaxis was delayed until the morning after surgery. Clinically relevant bleeding rates were similar, but a trend suggested fewer major bleeds with initiation of fondaparinux delayed to the morning after surgery.

CLINICAL IMPLICATIONS:  For this highly effective antithrombotic, delaying the first post-surgical dose until the morning after surgery did not appear to lessen clinical efficacy and may reduce major bleeding rates.

DISCLOSURE:  B. Davidson, Clinical research funds from Sanofi-Synthelabo

Wednesday, October 27, 2004

10:30 AM- 12:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
Guidelines
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543